Novartis keeps U.K. respiratory unit after layoffs

Novartis ($NVS) delivered some upbeat news to English workers and residents this week in confirming that the Swiss drug giant plans to keep a presence at its Horsham, U.K. site that has seen hundreds of jobs cut. While it plans to offload 12 acres from the campus for redevelopment, the drugmaker wants to keep its respiratory R&D operation with a focus on asthma, chronic bronchitis, and cystic fibrosis. Plus, the company aims to invest £5 million on improvements, the local West Sussex County Times reported. Still, many jobs at the historic site, particularly those in manufacturing, aren't coming back. Article